Physician profile
Vinod Kumar
NPI 1821544115
$4,413.24
in general payments reported to CMS, 2019-2025
46 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $275 · 2021: $738 · 2022: $154 · 2023: $116 · 2024: $1,852 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,526 · Education: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,526.26 |
| Education | $471.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $336.43 | 2020-2023 | Kyprolis |
| Incyte Corporation | $306.77 | 2019-2024 | Jakafi |
| Celgene Corporation | $303.99 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Lilly USA, LLC | $302.53 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $299.57 | 2019-2025 | |
| Daiichi Sankyo INC. | $281.86 | 2020-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $232.45 | 2021-2025 | Erleada, Rybrevant, Stelara |
| E.R. Squibb & Sons, L.L.C. | $191.83 | 2021-2025 | Opdivo |
| Seagen INC. | $154.99 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $137.77 | 2019-2025 | Calquence, Enhertu |
| Sobi, INC | $126.09 | 2024-2025 | |
| Fennec Pharmaceuticals, INC. | $114.74 | 2024-2025 | Fyarro, Pedmark |
| Abbvie INC. | $111.95 | 2020-2024 | |
| Array Biopharma INC | $105.91 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Eisai INC. | $105.06 | 2024-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.